Physician profile
Basit Rahim
NPI 1003253071
$1,423.07
in general payments reported to CMS, 2019-2025
17 companies · $262 in 2025
The $262 reported for 2025 was less than what a typical Vascular Neurology provider received nationally (typical 2025 total: $360).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2020: $21.86 · 2021: $185 · 2022: $80.60 · 2023: $731 · 2024: $18.90 · 2025: $262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $525 · Food and Beverage: $487.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $525.00 |
| Food and Beverage | $487.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ceribell, INC. | $525.00 | 2023 | Ceribell Rapid Response Eeg |
| Astrazeneca Pharmaceuticals Lp | $210.80 | 2021-2024 | Andexxa |
| Boston Scientific Corporation | $117.78 | 2021 | |
| Abbvie INC. | $114.69 | 2022-2025 | |
| Stryker Corporation | $111.94 | 2025 | Target |
| Kestra Medical Technology Services, INC. | $54.02 | 2025 | Assure Wcd |
| Adamas Pharmaceuticals, INC. | $46.41 | 2019 | |
| Chiesi USA, INC. | $46.36 | 2023-2025 | Cleviprex |
| Portola Pharmaceuticals, LLC | $34.44 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $27.97 | 2023 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.72 | 2025 | Jardiance |
| Merck Sharp & Dohme LLC | $24.28 | 2021 | |
| Biogen, INC. | $23.96 | 2019 | |
| Genzyme Corporation | $21.86 | 2020 | |
| Lundbeck LLC | $18.99 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Microtransponder, INC. | $16.85 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Basit Rahim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.